Evidence map›Paper›PMID 32143993›Full record

ArticleAcademic radiology2021

Quality of Prostate MRI: Is the PI-RADS Standard Sufficient?

Jonathan Sackett, Joanna H Shih, Sarah E Reese, Jeffrey R Brender, Stephanie A Harmon, Tristan Barrett, Mehmet Coskun, Manuel Madariaga, Jamie Marko, Yan Mee Law and 8 more

Abstract read
In one paragraph

Article in Academic radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jonathan SackettMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA; Loma Linda University School of Medicine, Loma Linda, CA, USA.
Joanna H ShihDivision of Cancer Treatment and Diagnosis: Biometric Research Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Sarah E ReeseGeneral Dynamics Information Technology, Falls Church, VA, USA.
Jeffrey R BrenderRadiation Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Stephanie A HarmonMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA; Leidos Biomedical Research, Inc., NCI Campus at Frederick, Clinical Research Directorate/Clinical Monitoring Research Program, Bethesda, MD, USA.
Tristan BarrettUniversity of Cambridge School of Clinical Medicine, Cambridge UK.
Mehmet CoskunDepartment of Radiology, Dr. Behcet Uz Child Disease and Pediatric Surgery Training and Research Hospital, University of Health Sciences, izmir, Turkey.
Manuel MadariagaDepartment of Radiology, San Jose Hospital, Santiago, Chile.
Jamie MarkoDepartment of Radiology, Clinical Center, NIH, Bethesda, MD, USA.
Yan Mee LawDepartment of Diagnostic Radiology, Singapore General Hospital, Singapore.
Evrim B TurkbeyDepartment of Radiology, Clinical Center, NIH, Bethesda, MD, USA.
Sherif MehralivandMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Thomas SanfordMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Nathan LayMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Peter A PintoUrologic Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
Bradford J WoodDepartment of Radiology, Clinical Center, NIH, Bethesda, MD, USA; Center for Interventional Oncology, National Cancer Institute, Bethesda, MD, USA.
Peter L ChoykeMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Baris TurkbeyMolecular Imaging Program, National Cancer Institute, NIH, Bethesda, MD, USA. Electronic address: turkbeyi@mail.nih.gov.

Funding

Prostate Cancer ImagingZIABC010655 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CHOYKE, PETER L · 2009 to 2025
$49.2M
Center for Interventional OncologyZIDBC011242 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WOOD, BRADFORD J · 2009 to 2025
$18.7M
Prostate SectionZIABC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2009 to 2025
$15.2M
Imaging, image guided biopsy and treatment of prostate cancerZIABC012062 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI TÜRKBEY, BARIS · 2021 to 2025
$1.3M
Prostate SectionZ01BC011081 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PINTO, PETER · 2008 to 2008
$99k
Interventional OncologyZIACL040015 · CLC · CLINICAL CENTER · PI WOOD, BRADFORD · 2009 to 2025
$0k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z01 BC011081Intramural NIH HHS ZIA BC010655Intramural NIH HHS ZID BC011242NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

RATIONALE AND

objectiveThe Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) published a set of minimum technical standards (MTS) to improve image quality and reduce variability in multiparametric prostate MRI. The effect of PIRADSv2 MTS on image quality has not been validated. We aimed to determine whether adherence to PI-RADSv2 MTS improves study adequacy and perceived quality. MATERIALS AND

methodsSixty-two prostate MRI examinations including T2 weighted (T2W) and diffusion weighted image (DWI) consecutively referred to our center from 62 different institutions within a 12-month period (September 2017 to September 2018) were included. Six readers assessed images as adequate or inadequate for use in PCa detection and a numerical image quality ranking was given using a 1-5 scale. The PI-RADSv2 MTS were synthesized into sets of seven and 10 rules for T2W and DWI, respectively. Image adherence was assessed using Digital Imaging and Communications in Medicine (DICOM) metadata. Statistical analysis of survey results and image adherence was performed based on reader quality scoring (Kendall Rank tau-b) and reader adequate scoring (Wilcoxon test for association) for T2 and DWI quality assessment.

resultsOut of 62 images, 52 (83%) T2W and 38 (61%) DWIs were rated to be adequate by a majority of readers. Reader adequacy scores showed no significant association with adherence to PI-RADSv2. There was a weak (tau-b = 0.22) but significant (p value = 0.01) correlation between adherence to PIRADSv2 MTS and image quality for T2W. Studies following all PI-RADSv2 T2W rules achieved a higher median average quality score (3.58 for 7/7 vs. 3.0 for <7/7, p = 0.012). No statistical relationship with PI-RADSv2 MTS adherence and DWI quality was found.

conclusionAmong 62 sites performing prostate MRI, few were considered of high quality, but the majority were considered adequate. DWI showed considerably lower rates of adequate studies in the sample. Adherence to PI-RADSv2 MTS did not increase the likelihood of having a qualitatively adequate T2W or DWI.

Indexed as

Magnetic Resonance ImagingProstatic NeoplasmsDiffusion Magnetic Resonance ImagingHumansMaleReference StandardsRetrospective StudiesDiffusion weighted imagingMRIPI-RADSProstateQuality control

Identifiers

PMID32143993
PMCPMC8459209

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.